Harvard T.H. Chan School of Public Health

TriNetX Announces the Appointment of Dr. K. Arnold Chan as Senior Vice President, Real-World Evidence Consulting

Retrieved on: 
Wednesday, June 7, 2023
Real-World Evidence, IEG, Private sector, Pharmacoepidemiology, NTU, Senior, National Taiwan University, Insight, International Society of Sculptors, Painters and Gravers, University, Research, Harvard T.H. Chan School of Public Health, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Public health, Faculty, National Perinatal Epidemiology Unit, Optum, Epidemiology, Arnold, Harvard School of Dental Medicine, Medical research, Management

CAMBRIDGE, Mass., June 7, 2023 /PRNewswire/ -- TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today announced that Dr. K. Arnold Chan joined the company as Senior Vice President, Real-World Evidence Consulting.

Key Points: 
  • CAMBRIDGE, Mass., June 7, 2023 /PRNewswire/ -- TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today announced that Dr. K. Arnold Chan joined the company as Senior Vice President, Real-World Evidence Consulting.
  • "Arnold brings over 30 years of global research experience across academia and the private sector to the TriNetX Insights and Evidence Generation (IEG) team ," said Jeffrey Brown, Chief Scientific Officer, TriNetX.
  • "We are thrilled to have him lead and grow the IEG team to support our customers' research needs."
  • "I am pleased to be a part of the Insights and Evidence Generation team at TriNetX," said Dr. Chan.

Transforming Patient Care: 5,000 Trained in Nonprofit Gaples Institute's Nutrition Course for Physicians

Retrieved on: 
Tuesday, June 6, 2023
Epidemiology, Curriculum, Public, Harvard T.H. Chan School of Public Health, Nutrition, Public health, Health, Physician, Patient, Risk, Education, Harvard University, Health policy, Nursing

"The fact that 97% of learners report that it will change their practice is a testament to the impact our nutrition course is making on patient care," said course director Dr. Stephen Devries, preventive cardiologist, Gaples Institute executive director, and Harvard T.H.

Key Points: 
  • "The fact that 97% of learners report that it will change their practice is a testament to the impact our nutrition course is making on patient care," said course director Dr. Stephen Devries, preventive cardiologist, Gaples Institute executive director, and Harvard T.H.
  • "It's exhilarating to receive such consistent feedback about how the course has enabled physicians to help their patients so profoundly."
  • The Gaples Institute nutrition course "fills a serious void in our medical education," according to Dr. Walter Willett, Professor of Nutrition and Epidemiology at the Harvard T.H.
  • The nonprofit Gaples Institute is supported by a board of internationally renowned leaders in nutrition science, education, and health policy and neither seeks nor accepts corporate funding.

DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

Retrieved on: 
Tuesday, May 30, 2023
FDA, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Chief scientific officer, Collateral circulation, DMAC, University, Senior, Internal medicine, Patient-Centered Outcomes Research Institute, Harvard T.H. Chan School of Public Health, Stroke, TPA, Harvard University, Associate, Bangladesh Technical Education Board, Harvard Medical School, NYSE, Master of Science, Public health, Miami University, Publication, National academy, Beth Israel Hospital, Patient, Division, Neuromodulation, PCORI, Executive Committee, Case Western Reserve University School of Medicine, S-1 Executive Committee, Biostatistics, HEAL, Neurology, NIH, Interventional cardiology, Pharmaceutical industry, Nursing, Science, Medtronic, Brigham, Parkland Memorial Hospital, Medicine

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.
  • Dr. Richard Kuntz recently retired from Medtronic plc (NYSE:MDT) where he was the Chief Medical Officer & Scientific Officer and a member of the Executive Committee.
  • Prior to that, he served as Senior Vice President and President, Neuromodulation of Medtronic from October 2005 to August 2009.
  • Before joining Medtronic, he was the founder and Chief Scientific Officer of the Harvard Clinical Research Institute in Boston.

St. Joseph's Hospital Appoints New Vice President, Chief Medical Officer

Retrieved on: 
Tuesday, May 16, 2023
University, Hospital medicine, St. Joseph's Hospital, Harvard T.H. Chan School of Public Health, American Academy, Geisinger Health System, Harvard University, American College of Physicians, Public health, Damascus School, MD, HCA, BayCare Ballpark, HCA Florida Kendall Hospital, Hospital, American College, Nursing, Physician, Medicine

TAMPA, Fla., May 16, 2023 /PRNewswire/ -- Samir Akach, MD, MHCM, has been selected as vice president and chief medical officer for St. Joseph's Hospital.

Key Points: 
  • TAMPA, Fla., May 16, 2023 /PRNewswire/ -- Samir Akach, MD, MHCM, has been selected as vice president and chief medical officer for St. Joseph's Hospital.
  • Dr. Akach has 15 years of physician leadership experience in non-profit, academic and integrated health care organizations and community-based, for-profit systems.
  • Prior to joining St. Joseph's Hospital, he served in a leadership role at HCA Florida JFK Hospital and HCA Florida JFK North Hospital in Palm Beach County.
  • "Dr. Akach's commitment to patient care aligns with the goals and values of St. Joseph's Hospital," said Dr. Sowmya Viswanathan, chief physician executive, BayCare Health System.

Consonance Capital Partners Adds Eric Van Horn to Operating Council

Retrieved on: 
Monday, May 15, 2023
General Health, Finance, Banking, Health, Professional Services, University of California, San Diego, Partnership, CMS, University, Senior, Centers for Medicare & Medicaid Services, University of California, Irvine Medical Center, Partner, Anderson School, Pharmacy, UCLA Anderson School of Management, National Operations Council, Sale, Decision Sciences, Medicare, CareMore, Public health, Community, Harvard T.H. Chan School of Public Health, Physician, Risk, School, Senior Advisor to the President of the United States, Growth, Entrepreneurship, Center for Medicare and Medicaid Innovation, Mitchell J. Blutt, Economics, Management

Consonance Capital Partners, a leading U.S.-based healthcare private equity firm, today announced that it has added health care leader Eric Van Horn to its Operating Council.

Key Points: 
  • Consonance Capital Partners, a leading U.S.-based healthcare private equity firm, today announced that it has added health care leader Eric Van Horn to its Operating Council.
  • Consonance Capital Partners’ Operating Council and Senior Advisory Board members work closely with the firm’s investment professionals, bringing valuable market insights, helping to source and diligence deals, and advising portfolio company management teams and serving on their boards of directors.
  • “Eric has unique and differentiated experience in advanced care models that help bring high quality care and superior outcomes to the medically frail population which is core to what we work to do at Consonance Capital Partners.
  • Eric joins a deep bench of senior healthcare executives and experts at Consonance Capital Partners.

NeuroTrauma Sciences Announces Key Appointments to its Executive Leadership Team

Retrieved on: 
Wednesday, May 10, 2023
Harvard School of Dental Medicine, PPD, KU Leuven, Research and development, NTS, Medical Affairs Bureau, Pfizer, Senior, University of Brussels, Traumatic brain injury, Université Laval, Stroke, New product development, MBA, Thermo Fisher Scientific, CMO, Concordia University, Harvard T.H. Chan School of Public Health, CNS, DSM-IV codes, Bachelor of Science, Central nervous system, Eisai, Public health, Doctor of Science, MD, Columbia Business School, Tropical medicine, Master of Science, Bernhard Nocht Institute for Tropical Medicine, Quality assurance, Growth, Shirin David, Merck, Regulatory affairs, Biostatistics, MPH, VC, Epidemiology, Imperial College London, Injury, Management, Pharmaceutical industry, Neuroscience

Dr. de Somer brings more than 30 years of leadership in the biopharmaceutical industry to the NTS management team in his role as Chief Medical Officer.

Key Points: 
  • Dr. de Somer brings more than 30 years of leadership in the biopharmaceutical industry to the NTS management team in his role as Chief Medical Officer.
  • He held clinical development leadership responsibilities in Europe, the UK, and the US at Sandoz/Novartis Pharmaceuticals.
  • "We are pleased to welcome these industry veterans to our leadership team," said Carl Long, Chief Executive Officer.
  • We will value their leadership and direction as we advance NTS-104 through the clinic."

Study Led by Global Communities Generates Novel Evidence on Gender Equality in the Context of Nutrition and Parenting Programs

Retrieved on: 
Tuesday, May 9, 2023
Medicine, Communication, Private sector, Project Concern International, Violence, Interview, Household, Community, Senior advisor, Empowerment, Research, South Africa Academy cricket team in Pakistan in 2005–06, Language, Mother, Harvard T.H. Chan School of Public Health, Public health, Journal, Child, Randomized controlled trial, Father, Purdue University, Global Communities, PCIA-II/MAP Modifying Attributions of Parents Intervention, Social science, Spring, Toy, Nursing, MD

The article titled “Effects of Engaging Fathers and Bundling Nutrition and Parenting Interventions on Household Gender Equality and Women's Empowerment in Rural Tanzania” resulted from a randomized controlled trial designed and implemented by Global Communities in collaboration with Harvard T.H.

Key Points: 
  • The article titled “Effects of Engaging Fathers and Bundling Nutrition and Parenting Interventions on Household Gender Equality and Women's Empowerment in Rural Tanzania” resulted from a randomized controlled trial designed and implemented by Global Communities in collaboration with Harvard T.H.
  • Chan School of Public Health, Purdue University, the Africa Academy for Public Health and the National Institute of Medical Research-Mwanza.
  • “Engaging men in gender-intentional nutrition and parenting programs takes effort and resources, but it can produce transformative results,” study author Nilupa Gunaratna of Purdue University said.
  • For more information, read an interview with the primary author and watch the EFFECTS webinar organized by Global Communities.

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

Retrieved on: 
Monday, May 8, 2023
Lymphoma, Marker, University, ARTEMIS, Internal medicine, Stanford University, MedImmune, Inc. v. Genentech, Inc., Biotechnology, Non-Hodgkin lymphoma, Clinical trial, Cancer, Drug, Chapel Hill, CMO, University of North Carolina School of Law, Trial of the century, Acute myeloid leukemia, AML, M.D, Public health, Monic, Harvard T.H. Chan School of Public Health, Geron Corporation, Johns Hopkins University, Patient, Division, School, Hematology, Haematopoietic system, Therapy, Bone marrow, Pharmaceutical industry, Medical imaging, Blood, Genentech, Biology

HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer.

Key Points: 
  • HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer.
  • “As we undergo a strategic review of our clinical programs, we are thrilled to add Monic to the leadership team at Marker Therapeutics and look forward to benefitting from her deep scientific, industry, and medical knowledge to drive our multiTAA-specific T cell product pipeline across multiple high-need cancer indications,” said Juan F. Vera, M.D., Chief Executive Officer of Marker Therapeutics.
  • Before her role at Geron Corp., she worked at Genentech Inc. as a Senior Medical Director in the Oncology Division.
  • She completed her medical residency in internal medicine and fellowships in hematology and bone marrow transplantation at Stanford University.

Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors

Retrieved on: 
Wednesday, May 3, 2023
Centers for Disease Control and Prevention, IQVIA, CTCL, Federal, Harvard T.H. Chan School of Public Health, National Institutes of Health, Doctor of Philosophy, Bangladesh Technical Education Board, Sale, Howard University College of Medicine, CDC, Syracuse University, Public health, PTX, Knowledge, Ulcer, Rare, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NIH, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Food, Pharmaceutical industry, Pentoxifylline

PRINCETON, N.J., May 3, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Timothy R. Coté, M.D., M.P.H. to its Board of Directors. 

Key Points: 
  • In this role, he implemented the U.S. Orphan Drug Act and personally signed decisions on more than 1,400 orphan drug designation applications.
  • "I am eager to be joining the Soligenix Board of Directors at such an important time for the Company," stated Dr. Coté.
  • "We are pleased to welcome Dr. Coté to the Soligenix Board," stated Christopher J. Schaber, PhD, President and CEO of Soligenix.
  • We believe his knowledge will add significantly to our already experienced Board of Directors and management team."

Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors

Retrieved on: 
Wednesday, May 3, 2023
Research, Technology, Clinical Trials, Software, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Doctor of Philosophy, Harvard T.H. Chan School of Public Health, Organism, Harvard University, Cancer, Dana–Farber Cancer Institute, Public health, Publication, Patient, Medicine, Harvard Department of Social Relations, Computational biology, Pharmaceutical industry, Biostatistics

Exscientia plc (Nasdaq: EXAI) today announced the appointment of Professor Franziska Michor, Ph.D. to its Board of Directors.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) today announced the appointment of Professor Franziska Michor, Ph.D. to its Board of Directors.
  • Prof. Michor is a professor of Computational Biology in the Department of Data Science at the Dana-Farber Cancer Institute, in the Department of Biostatistics at the Harvard T.H.
  • Chan School of Public Health, and in the Department of Stem Cell and Regenerative Biology at Harvard University.
  • “We are delighted to welcome Prof. Michor to our Board.